These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 16834823)
1. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Brankin E; Walker M; Lynch N; Aspray T; Lis Y; Cowell W Curr Med Res Opin; 2006 Jul; 22(7):1249-56. PubMed ID: 16834823 [TBL] [Abstract][Full Text] [Related]
2. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Cramer JA; Lynch NO; Gaudin AF; Walker M; Cowell W Clin Ther; 2006 Oct; 28(10):1686-94. PubMed ID: 17157124 [TBL] [Abstract][Full Text] [Related]
3. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Cramer JA; Amonkar MM; Hebborn A; Altman R Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664 [TBL] [Abstract][Full Text] [Related]
4. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Cramer JA; Gold DT; Silverman SL; Lewiecki EM Osteoporos Int; 2007 Aug; 18(8):1023-31. PubMed ID: 17308956 [TBL] [Abstract][Full Text] [Related]
5. Factors contributing to compliance with osteoporosis medication. Kertes J; Dushenat M; Vesterman JL; Lemberger J; Bregman J; Friedman N Isr Med Assoc J; 2008 Mar; 10(3):207-13. PubMed ID: 18494234 [TBL] [Abstract][Full Text] [Related]
6. Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Gold DT; Safi W; Trinh H Curr Med Res Opin; 2006 Dec; 22(12):2383-91. PubMed ID: 17257452 [TBL] [Abstract][Full Text] [Related]
7. Influence of patient training on persistence, compliance, and tolerability of different dosing frequency regimens of bisphosphonate therapy: An observational study in Turkish patients with postmenopausal osteoporosis. Akarırmak Ü; Koçyiğit H; Eskiyurt N; Esmaeilzadeh S; Kuru Ö; Yalçinkaya EY; Peker Ö; Ekim AA; Özgirgin N; Çalış M; Rezvani A; Çevikol A; Eyigör S; Şendur ÖF; İrdesel J; Acta Orthop Traumatol Turc; 2016 Aug; 50(4):415-23. PubMed ID: 27524671 [TBL] [Abstract][Full Text] [Related]
8. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Recker RR; Gallagher R; MacCosbe PE Mayo Clin Proc; 2005 Jul; 80(7):856-61. PubMed ID: 16007889 [TBL] [Abstract][Full Text] [Related]
9. [Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment]. Bartl R; Götte S; Hadji P; Hammerschmidt T Dtsch Med Wochenschr; 2006 Jun; 131(22):1257-62. PubMed ID: 16755420 [TBL] [Abstract][Full Text] [Related]
10. Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Penning-van Beest FJ; Erkens JA; Olson M; Herings RM Curr Med Res Opin; 2008 May; 24(5):1337-44. PubMed ID: 18380910 [TBL] [Abstract][Full Text] [Related]
11. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies. Cosman F; Borges JL; Curiel MD Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726 [TBL] [Abstract][Full Text] [Related]
12. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644 [TBL] [Abstract][Full Text] [Related]
13. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates. Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365 [TBL] [Abstract][Full Text] [Related]
14. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Emkey RD; Ettinger M Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937 [TBL] [Abstract][Full Text] [Related]
15. Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy. Gold DT; Trinh H; Safi W Curr Med Res Opin; 2009 Aug; 25(8):1831-9. PubMed ID: 19530982 [TBL] [Abstract][Full Text] [Related]
16. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System. Devine J; Trice S; Finney Z; Yarger S; Nwokeji E; Linton A; Davies W Osteoporos Int; 2012 Apr; 23(4):1415-24. PubMed ID: 21786005 [TBL] [Abstract][Full Text] [Related]
17. Switch patterns of osteoporosis medication and its impact on persistence among postmenopausal women in the U.K. General Practice Research Database. Li L; Roddam A; Ferguson S; Feudjo-Tepie M; Taylor A; Jick S Menopause; 2014 Oct; 21(10):1106-13. PubMed ID: 24569621 [TBL] [Abstract][Full Text] [Related]
18. Compliance with drug therapy for postmenopausal osteoporosis. Weycker D; Macarios D; Edelsberg J; Oster G Osteoporos Int; 2006; 17(11):1645-52. PubMed ID: 16862397 [TBL] [Abstract][Full Text] [Related]
19. Persistence with osteoporosis medications among postmenopausal women in the UK General Practice Research Database. Li L; Roddam A; Gitlin M; Taylor A; Shepherd S; Shearer A; Jick S Menopause; 2012 Jan; 19(1):33-40. PubMed ID: 21926926 [TBL] [Abstract][Full Text] [Related]
20. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009. Lee S; Glendenning P; Inderjeeth CA Osteoporos Int; 2011 Mar; 22(3):741-53. PubMed ID: 20589368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]